February 2020

Optogenerapy > 2020 > February

The European Optogenerapy project has developed the first subcutaneous biophotonic implant using optogenetic technology to deliver doses of therapeutic proteins to patients with Multiple Sclerosis. The device has been pre-clinically validated and features a printed circuit board that activates a light source which controls therapeutic Interferon Beta (IFN-ß) protein production by genetically engineered cells confined within the implant. Biotza Gutiérrez, the consortium’s coordinator from Eurecat...

Read More